Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

• Saliva plays a key role in the homeostasis of the digestive tract

• The reflux of gastroesophageal contents may cause damage to the esophageal, laryngeal and pharyngeal mucosas

• There seems to be no correlation between the severity of reflux episodes and the intensity of inflammatory changes, suggesting individual protective mechanisms to refluxate exposure

• Inorganic and Organic Salivary changes have been associated to Gastroesophageal Reflux Disease (GERD) and its supraesophageal manifestations, especially reflux laryngitis (Laryngopharyngeal Reflux- LPR)

• Decreased salivary Epidermal Growth factor (EGF) concentrations have been found in patients with GERD and LPR, but it is unclear if these are primary or secondary to the disease.

• Hypothesis: The decreased salivary EGF concentrations in patients with reflux laryngitis is primary and therefore would not change after treatment and control of the disease

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Faculdade de Ciências Médicas da Santa Casa de São Paulo
• Treatments: Mitogens; Omeprazole

Criteria

Inclusion Criteria:

• study group:

• symptoms of reflux laryngitis (Reflux Symptom Index- RSI >13) and videolaryngoscopic signs (Reflux Finding Score - RFS >7),

• positive 24 hour double probe esophageal PH monitoring;

• control group:

• Reflux Symptom Index (RSI)<13

• Reflux Finding Score (RFS) < 7

Exclusion Criteria:

• tobacco, alcohol or other inhaled drug use;

• chronic or acute rhinosinusitis;

• prior history of surgery to the digestive tract or salivary glands;

• prior or current diagnosis of head and neck or digestive tract tumors;

• chronic use of drugs known to alter salivary flow and irritate the larynx, such as, diuretics, anticonvulsants, antihistamines, and inhaled steroids